Table 2.
Characteristics of Participants in the Pilot Randomized Controlled Trial (N=40)
| Characteristic | Total | CBT-I | EUC | Test Statistic | P |
|---|---|---|---|---|---|
| Sociodemographic Characteristics | |||||
| Age (years), M (SD) | 53.2 (14.1) | 51.2 (17.1) | 55.3 (10.3) | t = −.91 | .37 |
| Gender (female) | 34 (85.0%) | 18 (90.0%) | 16 (80.0%) | X2 = .78 | .38 |
| Ethnicity (Hispanic) | 5 (12.5%) | 3 (15.0%) | 2 (10.0%) | X2 = .23 | .63 |
| Race* | X2 = .29 | .86 | |||
| White | 34 (85.0%) | 18 (90.0%) | 16 (80.0%) | ||
| Latinx | 4 (10.0%) | 2 (10.0%) | 2 (10.0%) | ||
| Asian | 2 (5.0%) | 1 (5.0%) | 1 (5.0%) | ||
| Africana | 1 (2.5%) | 0 (0.0%) | 1 (5.0%) | ||
| Married/Living as married | 29 (72.5%) | 12 (60.0%) | 17 (85.0%) | X2 = 3.13 | .08 |
| Number in household, M (SD) | 2.7 (1.2) | 2.6 (1.2) | 2.9 (1.1) | t = .82 | .42 |
| Completed college | 33 (82.5%) | 16 (80.0%) | 17 (85.0%) | X2 = .17 | .68 |
| Employed (at least part-time) | 21 (52.5%) | 5 (25.0%) | 16 (80.0%) | X2 = 12.13 | < .001 |
| Private insurance | 30 (75.0%) | 11 (55.0%) | 19 (95.0%) | X2 = 8.53 | < .01 |
| Medical Characteristics | |||||
| Cancer type* | X2 = 5.85 | .83 | |||
| Breast | 26 (65.0%) | 13 (65.0%) | 13 (65.0%) | ||
| Hematological | 5 (12.5%) | 2 (10.0%) | 3 (15.0%) | ||
| Thyroid | 4 (10.0%) | 3 (15.0%) | 1 (5.0%) | ||
| Prostate | 3 (7.5%) | 1 (5.0%) | 2 (10.0%) | ||
| Skin | 3 (7.5%) | 1 (5.0%) | 2 (10.0%) | ||
| Bladder | 2 (5.0%) | 1 (5.0%) | 1 (5.0%) | ||
| Ovary | 2 (5.0%) | 1 (5.0%) | 1 (5.0%) | ||
| Lung | 1 (2.5%) | 1 (5.0%) | 0 (0.0%) | ||
| Testicular | 1 (2.5%) | 1 (5.0%) | 0 (0.0%) | ||
| Urethra | 1 (2.5%) | 0 (0.0%) | 1 (5.0%) | ||
| Uterus | 1 (2.5%) | 0 (0.0%) | 1 (5.0%) | ||
| Time since diagnosis (months), M (SD) | 93.5 (91.7) | 92.5 (112.0) | 94.5 (68.7) | t = .07 | .94 |
| Time since treatment (months), M (SD) | 61.6 (61.5) | 53.0 (66.4) | 70.1 (56.5) | t = .88 | .39 |
| Cancer treatment type* | X2 = 2.80 | .83 | |||
| Surgery | 37 (92.5%) | 18 (90.0%) | 19 (95.0%) | ||
| Radiation therapy | 23 (57.5%) | 13 (65.0%) | 10 (50.0%) | ||
| IV chemotherapy/other IV cancer therapy | 22 (55.0%) | 11 (55.0%) | 11 (55.0%) | ||
| Hormonal or endocrine therapy | 18 (45.0%) | 10 (50.0%) | 8 (40.0%) | ||
| Oral chemotherapy/other oral therapy | 7 (17.5%) | 3 (15.0%) | 4 (20.0%) | ||
| Complementary or alternative therapy | 3 (7.5%) | 2 (10.0%) | 1 (5.0%) | ||
| Other | 2 (5.0%) | 2 (10.0%) | 0 (0.0%) | ||
| Comorbid medical illness (1+) | 22 (55.0%) | 9 (45.0%) | 13 (65.0%) | X2 = 1.62 | .20 |
| Comorbid psychiatric illness (1+) | 16 (40.0%) | 7 (35.0%) | 9 (45.0%) | X2 = .42 | .52 |
| COVID-19 diagnosis | 2 (5.0%) | 0 (0.0%) | 2 (10.0%) | X2 = 2.11 | .15 |
| Sleep Characteristics | |||||
| Insomnia severity (ISI), M (SD) | 18.0 (4.2) | 18.1 (4.6) | 17.9 (3.8) | t = −.19 | .85 |
| Sleep quality (PSQI Item 6), M (SD) | 2.1 (0.7) | 2.3 (0.6) | 2.0 (0.8) | t = −1.35 | .18 |
| Fatigue (FSI), M (SD) | 56.8 (28.4) | 55.7 (30.4) | 58.0 (26.9) | t = .26 | .80 |
Note.
*
Participants could select more than one response.